<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380665</url>
  </required_header>
  <id_info>
    <org_study_id>Prevena2009-45</org_study_id>
    <nct_id>NCT01380665</nct_id>
  </id_info>
  <brief_title>Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty</brief_title>
  <acronym>Prevena2009-45</acronym>
  <official_title>Prospective, Single Arm, Post-Marketing Trial to Examine the Safety and Functionality of the Prevena™ Incision Management System, A Negative Pressure Based Surgical Wound Management System, Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KCI USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this study is to evaluate the Prevena ™ 125 Unit and dressing system, when&#xD;
      applied to either the hip or knee area over a surgical cut for the time you are hospitalized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative pressure environment with accurate and reliable indicators;Dressing biocompatible with incision site and skin;Minimal dressing changes during therapy;Acceptable safety profile; minimal/no AEs;Patient comfort and dressing integrity after surgery</measure>
    <time_frame>during hospitalization (up to 7 days) and thru follow-up 30 days after dressing removal</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Linear or Emi-linear Incisions</condition>
  <condition>Total Hip Arthroplasty</condition>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>There is one group of 100 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena Incisional Management System</intervention_name>
    <description>All evaluable patients will utilize the Prevena Incisional Management System</description>
    <arm_group_label>There is one group of 100 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be ≥ 18 years of age&#xD;
&#xD;
          2. Subject must, at the treating physician's determination and definition, be an&#xD;
             appropriate Candidate for primary total hip or knee arthroplasty&#xD;
&#xD;
          3. Subjects who undergo primary total knee or hip arthroplasty must have a linear or&#xD;
             semi-linear incision whose length and curvature should fit within the dimensions bound&#xD;
             by the polyurethane foam (10 inches in length by 2.5 inches in width)&#xD;
&#xD;
          4. Subject is able and willing to provide written informed consent and comply with visit&#xD;
             schedule&#xD;
&#xD;
          5. Subject must agree to avoid application of tanning lotions or exposure of ultraviolet&#xD;
             radiation from sun or artificial sources such as a tanning bed on operative area for&#xD;
             the duration of study participation&#xD;
&#xD;
          6. Subject must not be pregnant if of child-bearing potential, or otherwise must be&#xD;
             surgically sterilized or unable to conceive. All females, regardless of child-bearing&#xD;
             potential, will receive a urine hCG test 2 weeks prior to surgery and the test result&#xD;
             must be negative for pregnancy.&#xD;
&#xD;
          7. Subjects who are of child-bearing potential must be utilizing an acceptable method of&#xD;
             birth control (eg, birth control pills, condom with spermicide, diaphragm with&#xD;
             spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc) and be&#xD;
             willing to continue birth control for duration of study participation. If birth&#xD;
             control method is the form of birth control pills, shots, implants skin patches, or&#xD;
             IUD, the method must have been utilized for at least 30 days prior to study&#xD;
             participation.&#xD;
&#xD;
          8. Subject must be willing to wear loose fitting clothing for duration of treatment&#xD;
             period&#xD;
&#xD;
          9. Subject must be willing to comply with visit schedule for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive pregnancy test confirmed by hCG in urine&#xD;
&#xD;
          2. Current or past (30 days prior to surgery) within time of screening attempts to become&#xD;
             pregnant&#xD;
&#xD;
          3. Current local or systemic infection (eg, skin infections, sinus infections, urinary&#xD;
             tract infection, sepsis, etc)&#xD;
&#xD;
          4. Current or past (14 days prior to surgery) within time of screening topical treatments&#xD;
             on operative area (eg, laser hair or tattoo removal, sunless tanning lotions)&#xD;
&#xD;
          5. Current or past (14 days prior to surgery) steroid topical therapies on operative area&#xD;
&#xD;
          6. Current or past (30 days prior to surgery) use of oral steroids (NOTE: Use of&#xD;
             non-topical, ophthalmic or aerosol types of steroids (ie, inhaled corticosteroids) are&#xD;
             permitted at screening and throughout the clinical trial)&#xD;
&#xD;
          7. Current or past (72 hours prior to surgery) within surgery use of antihistamines&#xD;
&#xD;
          8. Current or past (30 days prior to surgery) within time of screening use of oral&#xD;
             Tetracycline or AcutaneTM or topical Tetracycline or AcutaneTM on the operative area&#xD;
&#xD;
          9. Presence of skin lesions or abnormalities on operative area&#xD;
&#xD;
         10. Current or past malignancy requiring immunosuppressant therapy or chemotherapy within&#xD;
             5 years within time of screening&#xD;
&#xD;
         11. Presence of excessive skin folds on operative area&#xD;
&#xD;
         12. Intentional exposure of the operative area to ultraviolet radiation (14 days prior to&#xD;
             surgery) within time of screening (ie, sunbathing or tanning bed)&#xD;
&#xD;
         13. Presence of sunburned or peeling skin on operative area&#xD;
&#xD;
         14. Tattoos on operative area&#xD;
&#xD;
         15. Presence of severe, raised scar tissue on operative area which may interfere with pre&#xD;
             and post skin evaluation assessments&#xD;
&#xD;
         16. Presence of an open wound prior to the index surgical procedure on operative area&#xD;
&#xD;
         17. Reported alcohol (≥ 3 drinks per day) or drug abuse within the past 6 months&#xD;
&#xD;
         18. Topical hypersensitivity or allergy to any disposable components of the dressing&#xD;
             system (eg, silver, polyurethane, polyester, or acrylic adhesive)&#xD;
&#xD;
         19. Topical hypersensitivity or allergy towards any medical adhesive&#xD;
&#xD;
         20. Current enrollment or past participation in this clinical study or any other study&#xD;
             within ≤30 days&#xD;
&#xD;
         21. Any systemic or local active dermatological disease that might interfere with the&#xD;
             evaluation of the operative area (eg, Meleney's ulcer, scleroderma, chronic urticaria,&#xD;
             psoriasis, skin cancer, eczema, seborrhea, or malignancy)&#xD;
&#xD;
         22. Connective tissue disease or collagen vascular disease (eg, Ehlers-Danlos syndrome,&#xD;
             systemic lupus erythematosus, rheumatoid arthritis)&#xD;
&#xD;
         23. Current or history of hematological disorders or conditions (eg, polycythemia vera,&#xD;
             thrombocythemia, sickle-cell disease)&#xD;
&#xD;
         24. Any Subject with conditions which can potentially result in abnormally pigmented skin&#xD;
             (eg, melasma, vitiligo, pityriasis versicolor)&#xD;
&#xD;
         25. Inability or refusal to wear loose fitting clothing for the duration of the treatment&#xD;
             period&#xD;
&#xD;
         26. Subjects in whom orthopaedic reconstruction is required in addition to total hip or&#xD;
             knee arthroplasty&#xD;
&#xD;
         27. Subjects who are having the total hip or knee arthroplasty as a result of acute&#xD;
             orthopaedic trauma&#xD;
&#xD;
         28. Subjects who have incurred acute orthopaedic trauma (ie, hip fracture) recently or at&#xD;
             any time&#xD;
&#xD;
         29. Subjects who have either acute or chronic open/active wounds present (including&#xD;
             biopsies, ulcerations, etc)&#xD;
&#xD;
         30. Subjects in whom the index procedure is a revision of a total hip or knee arthroplasty&#xD;
&#xD;
         31. Subjects in whom the primary or partial total hip or knee arthroplasty would also be&#xD;
             performed on the contra lateral knee or hip at the same time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevena</keyword>
  <keyword>Incision</keyword>
  <keyword>Management</keyword>
  <keyword>System</keyword>
  <keyword>total</keyword>
  <keyword>knee</keyword>
  <keyword>hip</keyword>
  <keyword>replacement</keyword>
  <keyword>Surgery</keyword>
  <keyword>Negative</keyword>
  <keyword>Pressure</keyword>
  <keyword>dressing</keyword>
  <keyword>KCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

